Welcome to our dedicated page for Praxis Precision Medicines SEC filings (Ticker: PRAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Praxis Precision Medicines filings document regulatory disclosures for a CNS-focused biopharmaceutical issuer with common stock listed on the Nasdaq Global Select Market under PRAX. Its Form 8-K and 8-K/A reports cover material events, operating and financial results, clinical and regulatory updates, capital-structure disclosures, and leadership or board changes.
The company’s filing record includes disclosures related to ulixacaltamide HCl for essential tremor, elsunersen in SCN2A developmental and epileptic encephalopathy, and broader pipeline programs in movement disorders and epilepsy. Proxy materials address annual meeting matters, board composition, committee assignments, executive compensation, equity awards and other governance subjects.
Praxis Precision Medicines, Inc. (Nasdaq: PRAX) filed a Form 8-K detailing the voting results from its 2025 Annual Meeting held on June 26, 2025. A quorum was present and all three management proposals passed.
- Proposal 1 – Election of Class II Directors: Dr. Jeffrey Chodakewitz was elected with 14,596,188 votes for and 2,998,186 withheld; Dr. Merit Cudkowicz received 17,499,300 votes for and 95,074 withheld. Both directors will serve until the 2028 annual meeting. Broker non-votes for each nominee totaled 778,152.
- Proposal 2 – Auditor Ratification: Ernst & Young LLP was re-appointed as independent registered public accounting firm for FY 2025 with 18,358,636 votes for, 7,630 against and 6,260 abstentions (no broker non-votes).
- Proposal 3 – Say-on-Pay (advisory): Executive compensation was approved with 10,671,320 votes for, 6,919,705 against, 3,349 abstentions and 778,152 broker non-votes.
No additional matters were brought before stockholders. The filing is primarily administrative and does not disclose financial performance, transactions, or strategic changes.